Wong’s vision for the future is ambitious yet practical. He hopes to make volunteering more accessible and inclusive, ...

Cassava Sciences has officially ended development of simufilam in Alzheimer’s disease, marking the end of a tumultuous era ...

If you’ve ever watched Shark Tank, you probably know Barbara Corcoran. On the show, she invests in businesses, but away from ...

While Cassava is stopping investigations into simufilam in Alzheimer’s disease, the therapy is now being evaluated in ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

NEW YORK (Reuters) -The biotechnology company Cassava Sciences failed on Wednesday to end a malicious prosecution lawsuit by ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Washington University-led research shows a small group of participants in an Alzheimer’s study experienced a significant ...

The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end. The company has reported top-line data from a second phase 3 trial of the drug ...

Cassava Sciences (NASDAQ:SAVA) said Tuesday it will shut down its Alzheimer's disease program by the end of the second quarter after another Phase 3 trial failure for simufilam, its lead ...

An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in ...

A new study reveals that visual sensitivity loss can predict dementia up to 12 years before diagnosis. Researchers found that ...